{
  "folder": "IC-299",
  "content": "{{knowledge objective\n|Identifiant=OIC-299-03-B\n|Item_parent=Intracranial tumours\n|Item_parent_short=Intra-cranial tumours\n|Rank=B\n|Title=Knowing the main histological types of brain tumours\n|Description=Meningioma and pituitary adenoma / low-grade and high-grade glial tumours (glioblastoma) / metastases\n|Rubric=Definition\n|Contributors=Dr Thi\u00e9baud PICART (Hospices Civils de Lyon),Dr Pierre ANTH\u00c9RIEU (Toulouse University Hospital),Pr Fran\u00e7ois VASSAL (Saint-Etienne University Hospital)\n|Order=3}}\n\n'''Meningioma:'''\n\n- Often benign, WHO grade 1\n\n- Development from arachnoid cells\n\n- Sex ratio: predominantly female\n\n- Peak incidence: between 50 and 70 years of age\n\n- Genesis favoured by the use of certain progestogens (cyproterone acetate)\n\n- Possibility of multiple localisations (meningiomatosis), in association with other histological varieties of tumours of the nervous system (e.g. schwannomas) as part of neurofibromatosis type 2 (phacomatosis).\n\n- MRI semiology: extra-parenchymal tumour; well circumscribed; base of dural implantation; dural thickening on contact = \"comet tail\" sign; homogeneous enhancement after injection of contrast (gadolinium).\n\n- Treatment essentially surgical in symptomatic forms or those showing radiological progression\n\n\n'''[[Pituitary adenoma]]:''''\n\n- Secreting (prolactinoma, GH, LH, FSH, ACTH or TSH adenoma) or non-secreting\n\n- Clinical signs :\n\no Endocrine syndrome: hypersecretion of a hormonal sector; insufficiency of one or more hormonal sectors, anterior and/or posterior to the pituitary gland(s).\n\no Mass syndrome, e.g. with compression of the optic chiasm (bitemporal hemianopia)\n\no Pituitary apoplexy (rarer)\n\n- First-line surgical treatment, except for prolactinoma = dopaminergic agonists. Correction of endocrine deficits +++.\n\n\n'''Low-grade and high-grade glioma (glioblastoma) of malignancy:''''\n\n- Development from glia cells :\n\no Astrocyte \u2192 astrocytoma\n\no Oligodendrocyte \u2192 oligodendroglioma\n\n- 4 grades according to the WHO classification :\n\no Grade 1 = benign\n\no Grade 2 = low grade malignancy (inevitable progression to grade 3 and 4)\n\no Grade 3 and 4 = high grade of malignancy\n\n- \u2192 2 subtypes of glioblastoma:\n\no Primary ''(de novo)'''\n\no Secondary = transformation of a low-grade glioma as it progresses; younger subjects\n\n- For glioblastoma (grade 4), the factors that improve prognosis are :\n\no Age < 70\n\no General and neurological condition preserved (Karnofsky index > 70%)\n\no Quality of surgical resection\n\nMolecular biology: IDH mutation (= secondary glioblastoma); MGMT gene promoter methylation, predicts sensitivity to chemotherapy.\n{| class=\"wikitable\"\n| colspan=\"2\" |\n|Peak incidence\n|Preferential topography\n|MRI semiology\n|Treatment\n|Prognosis\n|-\n| rowspan=\"2\" |\n\n\n\n\n\nGliomas\n\n'''LOW GRADE'''\n|Grade 1\n|< 20 years\n<br />\n|Infra tentorial\n|Mixed = cystic / solid\n\nEnhancement after contrast\n|Surgery\n|Healing if complete resection\n|-\n|Grade 2\n|20-40 years\n<br />\n|Super tentorial\n|T2 hypersignal T1 hyposignal No contrast enhancement\n|Surgery (maximal resection, if possible)\n\n+/- radiotherapy / chemotherapy\n<br />\n|Unstoppable progression to anaplasia (grades 3 and 4)\n|-\n| rowspan=\"2\" |\n\n\n\n\n\n\n'''Gliomas''' '''HIGH GRADE''''\n|Grade 3\n|30-50 years\n|Supra tentorial\n|Hypersignal T2 Hyposignal T1\n\nTaking of contrast\n|Surgery (maximal resection, if possible)\n\n+ radiotherapy / chemotherapy\n|Unstoppable progression to glioblastoma (grade 4)\n|-\n|Grade 4\n|Age 60-70\n|Super tentorial\n|Necrosis\n\nHeterogeneous contrast\n|Surgery (maximal resection, if possible)\n\n+ concomitant radio-chemotherapy (Stupp protocol)\n|Rapid local/regional spread\n\nOverall survival of 15 months\n|}\n'''Metastasis:'''\n\n- Main origins = cancers with a strong neurological tropism: bronchopulmonary, breast and melanoma\n\n- MRI: single or multiple tumour(s); cortico-subcortical location; heterogeneous enhancement after contrast injection, with cocardial appearance (central necrosis and peripheral contrast); peritumoral oedema +++; haemorrhagic revelation of melanoma and kidney cancer metastases.\n\n- Treatment :\n\no Depends on the number, location and volume of the metastasis(es) and the existence of neurological deficits.\n\no Arsenal = excisional surgery; focal (conformal or stereotactic) or pan-brain radiotherapy; systemic treatments (chemotherapy, hormone therapy, targeted therapies).",
  "question": {
    "question": "What is the typical age range for the peak incidence of meningioma?",
    "option_a": "20-40 years",
    "option_b": "30-50 years",
    "option_c": "40-60 years",
    "option_d": "50-70 years",
    "correct_option": "d"
  }
}